Elekta and Key Distributor Enter Agreement to Increase Production Efforts of Radiotherapy Technology in Russia

Stockholm, SWEDEN, October 29, 2012 – Elekta, a world leader in the design and manufacture of cancer treatment technology and software, and MSM-MEDIMPEX, a major Russian medical technology distributor, have announced their intention to set up production of radiotherapy equipment in Russia, with the intent to improve access to radiation therapy treatments to Russian citizens afflicted with cancer. Russia is the world’s ninth most populous country.

The announcement – a Memorandum of Understanding – specifies that Elekta and MSM-MEDIMPEX will work together to manufacture and assemble radiotherapy technology, in addition to a radiotherapy support/service infrastructure in Russia and eventually other Commonwealth of Independent States countries. This effort will amplify national initiatives (such as the National Oncology Program, RNOP, started in 2009) to modernize existing radiotherapy facilities, establish new treatment centers and extend training programs for clinical staff.

This strategy to improve cancer care in Russia will receive a significant boost by cooperating with the Moscow State University (MSU) on R&D projects, efforts that are designed to enhance and adapt Elekta technology to meet local needs. Training programs also will be developed with MSU and supervised by top Russian medical institutions.

Elekta is the number one provider of oncology equipment in Russia. Working with MSM-MEDIMPEX since 2006, Elekta has received orders for more than 60 linear accelerators and 100 treatment planning systems across the country, a trend that will continue within the framework of the RNOP and Elekta / MSM-MEDIMPEX initiatives.

“In line with the Russian government’s efforts to modernize and improve the oncology field, and within Elekta’s human care mission, Elekta is elated to bring its clinical solutions even closer to Russian patients,” says Elekta President and CEO, Tomas Puusepp. “Ultimately, this developing cancer management infrastructure will provide similar added value and high-tech processes as those in Elekta’s main supply center in the United Kingdom.”

“MSM is proud to announce this result of our long-term cooperation with Elekta,” says Professor Dmitry Balalykin, founder of MSM and Chairman of the Board of Directors. “We began distributing Elekta solutions several years ago and have together built a unique service, training and educational infrastructure, which reflects a responsible, long-term approach of both companies to the market. In addition to attracting radiotherapists and medical physicists, this infrastructure has resulted in the leading position of Elekta products in the radiation therapy market in Russia. Today, we take the next step to providing better support for patients.”

# # #

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on October 29, 2012.

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.

Press Releases


  PDF Version

For further information, please contact

Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451
Email: johan.anderssonmelbi@elekta.com
Time zone: CET: Central European Time